These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 34580975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
    Kraaijenhof J, Muskiet MHA, Tonneijck L, Ouwens DM, Kramer MHH, van Raalte DH, Smits MM.
    Diabetes Obes Metab; 2020 Oct; 22(10):1847-1856. PubMed ID: 32476255
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ.
    Diab Vasc Dis Res; 2015 May; 12(3):164-74. PubMed ID: 25780262
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
    Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, Marx N, McGuire DK, Andersen KR, Mattheus M, Keller A, Weber M, Johansen OE.
    Diabetes Obes Metab; 2021 Feb; 23(2):569-580. PubMed ID: 33185002
    [Abstract] [Full Text] [Related]

  • 9. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 10. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE.
    Cardiovasc Diabetol; 2021 Sep 04; 20(1):178. PubMed ID: 34481498
    [Abstract] [Full Text] [Related]

  • 11. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L, Muskiet MHA, Smits MM, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH.
    Diabetes Obes Metab; 2017 Dec 04; 19(12):1669-1680. PubMed ID: 28449402
    [Abstract] [Full Text] [Related]

  • 12. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
    Gallwitz B, Rosenstock J, Patel S, von Eynatten M, Hehnke U, Mehlburger L, Dugi KA, Woerle HJ.
    Diabetes Obes Metab; 2015 Mar 04; 17(3):276-84. PubMed ID: 25425502
    [Abstract] [Full Text] [Related]

  • 13. Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
    Sidelmann Christensen A, Storgaard H, Hædersdal S, Hansen T, Knop FK, Vilsbøll T.
    BMJ Open; 2018 Oct 03; 8(10):e022517. PubMed ID: 30287671
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ, Janssen J, van den Berg E, Zinman B, Espeland MA, Mattheus M, Johansen OE, CAROLINA® investigators.
    BMC Neurol; 2018 Jan 15; 18(1):7. PubMed ID: 29334906
    [Abstract] [Full Text] [Related]

  • 15. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul 15; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov 15; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 17. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH.
    Diabetologia; 2016 Jul 15; 59(7):1412-1421. PubMed ID: 27038451
    [Abstract] [Full Text] [Related]

  • 18. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 19. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T, Anastassiadis E, Diessel S, Löffler A, Pfützner A.
    Diabetes Metab Res Rev; 2014 Oct 14; 30(7):582-9. PubMed ID: 24459063
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 14; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.